These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 3192334)

  • 1. Mouse monoclonal antibodies for experimental immunotherapy promotes killing of tumor cells.
    Larson LN; Johansson C; Lindholm L; Holmgren J
    Int J Cancer; 1988 Dec; 42(6):877-82. PubMed ID: 3192334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes.
    Masui H; Moroyama T; Mendelsohn J
    Cancer Res; 1986 Nov; 46(11):5592-8. PubMed ID: 3756906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two distinct mechanisms of antitumor activity mediated by the combination of interleukin 2 and monoclonal antibodies.
    Vuist WM; van Buitenen F; Hekman A; Melief CJ
    Cancer Res; 1990 Sep; 50(18):5767-72. PubMed ID: 1697500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumour-growth suppression in nude mice by a murine monoclonal antibody: factors hampering successful therapy.
    Johansson C; Segrén S; Lindholm L
    Int J Cancer; 1991 May; 48(2):297-304. PubMed ID: 1708368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo.
    Drebin JA; Link VC; Greene MI
    Oncogene; 1988 Apr; 2(4):387-94. PubMed ID: 2896329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Both the epitope specificity and isotype are important in the antitumor effect of monoclonal antibodies against Her-2/neu antigen.
    Kim KM; Shin EY; Moon JH; Heo TH; Lee JY; Chung Y; Lee YJ; Cho HM; Shin SU; Kang CY
    Int J Cancer; 2002 Dec; 102(4):428-34. PubMed ID: 12402315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced antitumor effects of CD20 over CD19 monoclonal antibodies in a nude mouse xenograft model.
    Hooijberg E; van den Berk PC; Sein JJ; Wijdenes J; Hart AA; de Boer RW; Melief CJ; Hekman A
    Cancer Res; 1995 Feb; 55(4):840-6. PubMed ID: 7531616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells.
    Herlyn D; Koprowski H
    Proc Natl Acad Sci U S A; 1982 Aug; 79(15):4761-5. PubMed ID: 6289317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo destruction of canine lymphoma mediated by murine monoclonal antibodies.
    Steplewski Z; Rosales C; Jeglum KA; McDonald-Smith J
    In Vivo; 1990; 4(4):231-4. PubMed ID: 2103365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potentiation by interleukin 2 of Burkitt's lymphoma therapy with anti-pan B (anti-CD19) monoclonal antibodies in a mouse xenotransplantation model.
    Vuist WM; v Buitenen F; de Rie MA; Hekman A; Rümke P; Melief CJ
    Cancer Res; 1989 Jul; 49(14):3783-8. PubMed ID: 2472198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
    Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumors undergoing rejection induced by monoclonal antibodies of the IgG2a isotype contain increased numbers of macrophages activated for a distinctive form of antibody-dependent cytolysis.
    Adams DO; Hall T; Steplewski Z; Koprowski H
    Proc Natl Acad Sci U S A; 1984 Jun; 81(11):3506-10. PubMed ID: 6587365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of complement by monoclonal antibodies that target cell-associated β₂-microglobulin: implications for cancer immunotherapy.
    Pokrass MJ; Liu MF; Lindorfer MA; Taylor RP
    Mol Immunol; 2013 Dec; 56(4):549-60. PubMed ID: 23911412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies.
    Baselga J; Norton L; Masui H; Pandiella A; Coplan K; Miller WH; Mendelsohn J
    J Natl Cancer Inst; 1993 Aug; 85(16):1327-33. PubMed ID: 8340945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18.
    Mujoo K; Kipps TJ; Yang HM; Cheresh DA; Wargalla U; Sander DJ; Reisfeld RA
    Cancer Res; 1989 Jun; 49(11):2857-61. PubMed ID: 2720646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative binding and preclinical localization and therapy studies with radiolabeled human chimeric and murine 17-1A monoclonal antibodies.
    Buchsbaum DJ; Brubaker PG; Hanna DE; Glatfelter AA; Terry VH; Guilbault DM; Steplewski Z
    Cancer Res; 1990 Feb; 50(3 Suppl):993s-999s. PubMed ID: 2297753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapy with unlabeled and 131I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt's lymphoma xenografts.
    Buchsbaum DJ; Wahl RL; Normolle DP; Kaminski MS
    Cancer Res; 1992 Dec; 52(23):6476-81. PubMed ID: 1423295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric (mouse/human) anti-colon cancer antibody c30.6 inhibits the growth of human colorectal cancer xenografts in scid/scid mice.
    Mount PF; Sutton VR; Li W; Burgess J; McKEnzie IF; Pietersz GA; Trapani JA
    Cancer Res; 1994 Dec; 54(23):6160-6. PubMed ID: 7954462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the pharmacokinetics, biodistribution and dosimetry of monoclonal antibodies OC125, OV-TL 3, and 139H2 as IgG and F(ab')2 fragments in experimental ovarian cancer.
    Molthoff CF; Pinedo HM; Schlüper HM; Nijman HW; Boven E
    Br J Cancer; 1992 May; 65(5):677-83. PubMed ID: 1586596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunologic control of a retrovirus-associated murine adenocarcinoma. VI. Augmentation of antibody-dependent killing following quantitative and qualitative changes in host peritoneal cells.
    Matthews TJ; Weinhold KJ; Langlois AJ; Bolognesi DP
    J Natl Cancer Inst; 1985 Oct; 75(4):703-8. PubMed ID: 3862902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.